Table 3.
Subgroup analysis for visual acuity, visual gain and number of injections
| 12 months | 24 months | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Between group-difference (p) | Between group-difference (p) | |||||||||||||||||
| n | kS | Mean | SD | 95% CI | Bro-Ran | Bro-Afl | Ran-Afl | Ran-Afl-Bro | n | kS | Mean | SD | 95% CI | Bro-Ran | Bro-Afl | Ran-Afl | Ran-Afl-Bro | |
| Visual acuity (VA) | ||||||||||||||||||
| Ranibizumab 0.5 mg | 1415 | 8 | 67.9 | 11.5 | 66.1 to 69.7 | 0.99 | 0.59 | 0.64 | 0.86 | 568 | 4 | 67.7 | 18.5 | 65.1 to 70.3 | n.a. | n.a. | 0.11 | n.a. |
| Aflibercept 2.0 mg | 941 | 9 | 67.2 | 15.7 | 64.8 to 69.6 | 930 | 9 | 64.8 | 18.2 | 62.3 to 67.3 | ||||||||
| Brolucizumab 6.0 mg | 730 | 2 | 67.9 | 15.3 | 66.9 to 68.9 | mv | mv | mv | mv | mv | ||||||||
| VA gain | ||||||||||||||||||
| Ranibizumab 0.5 mg | 1443 | 8 | 7.6 | 12.7 | 5.6 to 9.6 | 0.43 | 0.44 | 0.86 | 0.61 | 1339 | 7 | 5.9 | 15.0 | 4.3 to 7.5 | 0.96 | 0.44 | 0.58 | 0.69 |
| Aflibercept 2.0 mg | 1151 | 11 | 7.4 | 12.3 | 6.0 to 8.8 | 2315 | 12 | 6.4 | 14.4 | 5.7 to 7.2 | ||||||||
| Brolucizumab 6.0 mg | 730 | 2 | 6.7 | 12.9 | 5.8 to 7.6 | 646 | 2 | 5.9 | 14.8 | 4.8 to 7.0 | ||||||||
| Number of injections | ||||||||||||||||||
| Ranibizumab 0.5 mg | 1415 | 9 | 9.0 | 2.3 | 8.6 to 9.4 | n.a. | n.a. | < 0.001 | n.a. | 1037 | 4 | 7.4 | 2.6 | 5.1 to 9.8 | n.a. | n.a. | 0.06 | n.a. |
| Aflibercept 2.0 mg | 1101 | 10 | 7.9 | 1.3 | 7.5 to 8.3 | 1920 | 9 | 5.2 | 2.0 | 4.6 to 5.8 | ||||||||
| Brolucizumab 6.0 mg | mv | mv | mv | mv1 | mv | mv | mv | mv | mv | mv | ||||||||
The p values represent the differences between all three groups
mv, missing value; n.a.. not applicable
1No information on the number of injections have been reported for brolucizumab (information could not be retrieved from the supplemental material either)